Site Editor

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

Neoadjuvant/Adjuvant Nivolumab With Chemotherapy Approved for Resectable NSCLC

By: JNCCN 360 Staff
Posted: Friday, October 4, 2024

Yesterday, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node-positive) non–small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements. For full prescribing information, visit accessdata.fda.gov.

Efficacy was evaluated in CheckMate 77T (ClinicalTrials.gov identifier NCT04025879), a randomized, double-blind, placebo-controlled multicenter trial in 461 patients with previously untreated and resectable NSCLC (stage IIA to select stage IIIB). Patients were randomly assigned (1:1) to receive nivolumab or placebo, with platinum-based chemotherapy, every 3 weeks for up to 4 cycles (neoadjuvant treatment), followed by either continued single-agent nivolumab or placebo every 4 weeks for up to 13 cycles (adjuvant treatment).

The major efficacy outcome measure was event-free survival by blinded independent central review. Median event-free survival was not reached (95% confidence interval [CI] = 28.9 months to not estimable) in the nivolumab arm and 18.4 months (95% CI = 13.6–28.1 months) in the chemotherapy arm (hazard ratio = 0.58 [95% CI = 0.43–0.78]; P = .00025). At the prespecified interim analysis, overall survival was not formally tested for statistical significance; however, a descriptive analysis revealed no detriment.

Adverse reactions were similar to those occurring in other clinical trials of nivolumab with chemotherapy. Of those who received nivolumab in the neoadjuvant setting, 5.3% were unable to undergo surgery because of adverse reactions compared with 3.5% in the placebo arm. In addition, 4.5% who received neoadjuvant treatment and surgery in the nivolumab arm had delays in surgery because of adverse reactions compared with 3.9% in the placebo arm.

The recommended dosage of nivolumab is 360 mg every 3 weeks (neoadjuvant treatment) and 480 mg every 4 weeks (adjuvant treatment). Nivolumab should be administered prior to chemotherapy when administered on the same day.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.